differentiated antibiotics

Cempra Completes Enrollment of Solitaire-Oral Phase 3 Trial

CHAPEL HILL, N.C., Sept. 25, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP) today announced the completion of enrollment of the global Solitaire-Oral Phase 3 clinical trial of oral solithromycin in adult patients with moderate to moderately severe community-acquired bacterial pneumonia (CABP).

Cempra, Inc. Receives $10 Million Milestone Payment From Toyama Chemical Co. Triggered by Solithromycin's Clinical Development Progress in Japan

CHAPEL HILL, N.C., Sept. 9, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP) today announced the receipt of a $10 million milestone payment from Toyama Chemical Co., a subsidiary of FUJIFILM Holdings Corporation, triggered by Toyama's progress of its solithromycin clinical development program in Japan, the world's second largest antibiotic market.